These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30385641)

  • 1. The Network Degeneration Hypothesis: Spread of Neurodegenerative Patterns Along Neuronal Brain Networks.
    Drzezga A
    J Nucl Med; 2018 Nov; 59(11):1645-1648. PubMed ID: 30385641
    [No Abstract]   [Full Text] [Related]  

  • 2. Classics in Neuroimaging: Untangling the Role of Tau in Neurodegenerative Disorders Using Positron Emission Tomography.
    Witek JA; Brooks AF; Scott PJH
    ACS Chem Neurosci; 2022 Oct; 13(19):2778-2783. PubMed ID: 36112411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach.
    Eidelberg D
    Trends Neurosci; 2009 Oct; 32(10):548-57. PubMed ID: 19765835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study.
    Tahmasian M; Shao J; Meng C; Grimmer T; Diehl-Schmid J; Yousefi BH; Förster S; Riedl V; Drzezga A; Sorg C
    J Nucl Med; 2016 Mar; 57(3):410-5. PubMed ID: 26585059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of
    Kuwabara H; Comley RA; Borroni E; Honer M; Kitmiller K; Roberts J; Gapasin L; Mathur A; Klein G; Wong DF
    J Nucl Med; 2018 Dec; 59(12):1877-1884. PubMed ID: 30097505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions.
    Rowley PA; Samsonov AA; Betthauser TJ; Pirasteh A; Johnson SC; Eisenmenger LB
    Semin Ultrasound CT MR; 2020 Dec; 41(6):572-583. PubMed ID: 33308496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.
    Parbo P; Ismail R; Sommerauer M; Stokholm MG; Hansen AK; Hansen KV; Amidi A; Schaldemose JL; Gottrup H; Brændgaard H; Eskildsen SF; Borghammer P; Hinz R; Aanerud J; Brooks DJ
    Neurobiol Dis; 2018 Sep; 117():211-216. PubMed ID: 29902557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.
    Villemagne VL; Doré V; Burnham SC; Masters CL; Rowe CC
    Nat Rev Neurol; 2018 Apr; 14(4):225-236. PubMed ID: 29449700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to special issue on The Role of Connectivity in Developmental Disorders: Genetic and Neural Network Approaches.
    Nelson CA
    Dev Sci; 2016 Jul; 19(4):523. PubMed ID: 27412227
    [No Abstract]   [Full Text] [Related]  

  • 11. Distinct influence of specific versus global connectivity on the different Alzheimer's disease biomarkers.
    Mutlu J; Landeau B; Gaubert M; de La Sayette V; Desgranges B; Chételat G
    Brain; 2017 Dec; 140(12):3317-3328. PubMed ID: 29194503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.
    Josephs KA; Whitwell JL; Tacik P; Duffy JR; Senjem ML; Tosakulwong N; Jack CR; Lowe V; Dickson DW; Murray ME
    Acta Neuropathol; 2016 Dec; 132(6):931-933. PubMed ID: 27645292
    [No Abstract]   [Full Text] [Related]  

  • 13. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.
    Coakeley S; Cho SS; Koshimori Y; Rusjan P; Harris M; Ghadery C; Kim J; Lang AE; Wilson A; Houle S; Strafella AP
    J Cereb Blood Flow Metab; 2017 Sep; 37(9):3150-3160. PubMed ID: 28155586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET biomarkers: Use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis.
    García-Ribas G; Arbizu J; Carrió I; Garrastachu P; Martinez-Lage P
    Neurologia; 2017 Jun; 32(5):275-277. PubMed ID: 27157520
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers.
    Shah M; Catafau AM
    J Nucl Med; 2014 Jun; 55(6):871-4. PubMed ID: 24833492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau imaging with PET: an overview of challenges, current progress, and future applications.
    Robertson JS; Rowe CC; Villemagne VL
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):405-413. PubMed ID: 28750496
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Edison P
    Brain Connect; 2020 Nov; 10(9):465-466. PubMed ID: 33210959
    [No Abstract]   [Full Text] [Related]  

  • 18. Developments in Tau PET Imaging.
    Zimmer ER; Leuzy A; Gauthier S; Rosa-Neto P
    Can J Neurol Sci; 2014 Sep; 41(5):547-53. PubMed ID: 25424608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging biomarkers in Alzheimer's disease: added value in the clinical setting.
    Morbelli S; Bauckneht M; Scheltens P
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):360-371. PubMed ID: 28750495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.